Krystal Biotech, Inc. (NASDAQ:KRYS)
| Market Cap | 9.50B+73.4% |
| Revenue (ttm) | 440.48M+22.6% |
| Net Income | 241.47M+64.6% |
| EPS | 7.98+62.2% |
| Shares Out | 29.48M |
| PE Ratio | 38.99 |
| Forward PE | 34.48 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 55,313.609 |
| Open | 321.61 |
| Previous Close | 324.57 |
| Day's Range | 319.58 - 326.50 |
| 52-Week Range | 179.19 - 382.54 |
| Beta | 0.50 |
| Analysts | Buy |
| Price Target | 395.20(+22.57%) |
| Earnings Date | Nov 2, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About KRYS
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$KRYS stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in KRYS holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by KRYS's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
KRYS Estimated quarterly lobbying spending
Source: U.S. Senate LDA
KRYS Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Product revenue, net | $119.22M | 93.96% |
| Interest and other income, net | $7.66M | 6.04% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New KRYS patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to KRYS from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in KRYS
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $320.34M |
| VBVanguard Morningstar Small-Cap ETF | $231.59M |
| IWMiShares Russell 2000 ETF | $222.45M |
| XBIState Street SPDR S&P Biotech ETF | $145.31M |
| VBKVanguard Morningstar Small-Cap Growth ETF | $132.90M |
| VXFVanguard Extended Market ETF | $109.54M |
Estimated from each fund’s disclosed top holdings × AUM
KRYS Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from KRYS’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score